SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives approval from USFDA for Oseltamivir Phosphate

21 Feb 2018 Evaluate

Lupin has received final approval for its Oseltamivir Phosphate for Oral Suspension from the United States Food and Drug Administration (USFDA) to market the generic version of Hoffman-La Roche, Tamiflu for Oral Suspension, 6 mg/mL. Oseltamivir Phosphate had annual sales of approximately Rs 35.80 crore in the US.

Oseltamivir Phosphate is for treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients 1 year and older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2469.00 26.65 (1.09%)
07-May-2026 12:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.80
Dr. Reddys Lab 1309.95
Cipla 1374.15
Zydus Lifesciences 941.40
Lupin 2469.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×